PBF-509   Click here for help

GtoPdb Ligand ID: 10193

Synonyms: PBF509
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: PBF-509 is an adenosine A2A receptor antagonist that is being developed by Palobiofarma [2-3]. It is being considered for clinical potential as an immuno-onclogy adjunctive agent and as a treatment for movement disorder in Parkinson's disease patients. Although the chemical structure of PBF-509 has not been formally disclosed, a comparision of published data and Palobiofarma patent documents leads us to consider Example 1 from WO2011121418A1 [1] as a likely candidate for this antagonist (binding and functional data values in the patent match data published in the peer reviewed articles that describe PBF-509). We await full disclosure to be certain of our decision.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 86.4
Molecular weight 305
XLogP 2.18
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Nc1nc(nc(c1Br)n1cccn1)n1cccn1
Isomeric SMILES Nc1nc(nc(c1Br)n1cccn1)n1cccn1
InChI InChI=1S/C10H8BrN7/c11-7-8(12)15-10(18-6-2-4-14-18)16-9(7)17-5-1-3-13-17/h1-6H,(H2,12,15,16)
InChI Key ATFXVNUWQOXRRU-UHFFFAOYSA-N
References
1. Gomez JAC, Laria JCC-P. (2011)
4-aminopyrimidine derivatives and their as as adenosine A2A receptor antagonists.
Patent number: WO2011121418A1. Assignee: Palobiofarma, S.L.. Priority date: 31/03/2010. Publication date: 06/10/2011.
2. Mediavilla-Varela M, Castro J, Chiappori A, Noyes D, Hernandez DC, Allard B, Stagg J, Antonia SJ. (2017)
A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment.
Neoplasia, 19 (7): 530-536. [PMID:28582704]
3. Núñez F, Taura J, Camacho J, López-Cano M, Fernández-Dueñas V, Castro N, Castro J, Ciruela F. (2018)
PBF509, an Adenosine A2A Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders.
Front Pharmacol, 9: 1200. [PMID:30405415]